化合物简介
Brexpiprazole (brand name Rexulti recks-UL-tee, previously known as OPC-34712) is a novel atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
基本信息
中文名称
依匹哌唑
英文名称
Brexpiprazole
中文别名
布雷帕唑、7-(4-(4-(苯并[B]噻吩-4-基-哌嗪-1-基)丁氧基)-1H-喹啉-2-酮、[依匹唑派]
英文别名
Rexulti、OPC-34712、7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1H)-Quinolinone、7-[4-[4-(1-Benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one、7-[4-(4-(Benzo[b]thien-4-yl)-piperazin-1-yl)butoxy]-1H-quinolin-2-one、7-(4-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
CAS号
913611-97-9
分子式
C25H27N3O2S
分子量
433.566
精确质量
433.182
PSA
77.07
LOGP
5.1392
编号系统
MDL号
MFCD27987920
